Cervical cancer is one of the most common malignant tumors among women worldwide, with particularly high incidence and mortality rates in developing countries. Early diagnosis and precise treatment of cervical cancer are critical for improving patient survival and quality of life. Current studies have identified tumor heterogeneity as a key factor influencing therapeutic outcomes in cervical cancer. Although conventional imaging modalities such as two-dimensional ultrasonography, CT, and MRI play important roles in tumor diagnosis and staging, they are limited in their ability to comprehensively reveal tumor heterogeneity. In recent years, the emergence of three-dimensional (3D) ultrasonography has provided a novel approach for precise tumor diagnosis and personalized treatment. Compared with traditional 2D ultrasonography, 3D ultrasonography can more accurately assess tumor morphology, volume, and boundaries, and can effectively distinguish between benign and malignant tumors through dynamic blood flow analysis. Thus, 3D ultrasonography offers clinicians more detailed spatial information about tumors and enables a more comprehensive evaluation of cervical cancer heterogeneity. Moreover, the integration of 3D ultrasonography with other imaging techniques, such as diffusion-weighted imaging (DWI), intravoxel incoherent motion (IVIM), and dynamic contrast-enhanced MRI (DCE-MRI), can further enhance the accuracy of early diagnosis, staging, and treatment response monitoring in cervical cancer.

Fang Lei. Research Progress of 3D Ultrasonography and Radiomics in the Analysis of Tumor Heterogeneity in Cervical Cancer. Frontiers in Medical Science Research (2025), Vol. 7, Issue 5: 23-28. https://doi.org/10.25236/FMSR.2025.070504.

[1] Burmeister CA, Khan SF, Schäfer G, et al. Cervical cancer therapies: Current challenges and future perspectives. Tumour Virus Res. 2022;13:200238.

[2] Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv72-iv83.

[3] Ramón Y Cajal S, Sesé M, Capdevila C, et al. Clinical implications of intratumor heterogeneity: challenges and opportunities. J Mol Med (Berl). 2020;98(2):161-177. 

[4] Wang Ruining, Zhang Qian, Liu Liping. Research progress of ultrasound radiomics in hepatocellular carcinoma [J]. Chinese Journal of Ultrasonography, 2025, 34(6): 547-552. 

[5] McEvoy A, Tetrokalashvili M. Anatomy, Abdomen and Pelvis: Female Pelvic Cavity. In: StatPearls. Treasure Island (FL): StatPearls Publishing; July 24, 2023.

[6] Kubitschke H, Wolf B, Morawetz E, et al. Roadmap to Local Tumour Growth: Insights from Cervical Cancer. Sci Rep. 2019;9(1):12768. 

[7] Ye J, Zheng L, He Y, Qi X. Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions. MedComm (2020). 2023;4(5):e368. 

[8] Campos-Parra AD, Pérez-Quintanilla M, Martínez-Gutierrez AD, et al. Molecular Differences between Squamous Cell Carcinoma and Adenocarcinoma Cervical Cancer Subtypes: Potential Prognostic Biomarkers. Curr Oncol. 2022;29(7):4689-4702.

[9] Bhatla N, Singhal S, Dhamija E, Mathur S, Natarajan J, Maheshwari A. Implications of the revised cervical cancer FIGO staging system. Indian J Med Res. 2021;154(2):273-283.

[10] Luo L, Luo Q, Tang L. Diagnostic value and clinical significance of MRI and CT in detecting lymph node metastasis of early cervical cancer. Oncol Lett. 2020;19(1):700-706.

[11] Wu VC, Takeuchi M. Three-Dimensional Echocardiography: Current Status and Real-Life Applications. Acta Cardiol Sin. 2017;33(2):107-118.

[12] Little SH, Igo SR, McCulloch M, Hartley CJ, Nosé Y, Zoghbi WA. Three-dimensional ultrasound imaging model of mitral valve regurgitation: design and evaluation. Ultrasound Med Biol. 2008; 34(4): 647-654.

[13] Tu E, Bagnall RD, Duflou J, Semsarian C. Post-mortem review and genetic analysis of sudden unexpected death in epilepsy (SUDEP) cases. Brain Pathol. 2011;21(2):201-208.

[14] Fang C, An J, Bruno A, et al. Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases. Hepatol Int. 2020;14(4):437-453.

[15] Arribas S, Alcázar JL, Arraiza M, Benito A, Minguez JA, Jurado M. Three-Dimensional Transvaginal Sonography and Magnetic Resonance Imaging for Local Staging of Cervical Cancer: An Agreement Study. J Ultrasound Med. 2016;35(5):867-873.

[16] Hu, Rong et al. “Diagnostic Value of Two-Dimensional Transvaginal Ultrasound Combined with Contrast-Enhanced Ultrasound in Ovarian Cancer.” Frontiers in surgery, vol. 9. 27 May. 2022,

[17] Mao Lijuan, Wang Wenping, Ding Hong, et al. Comparative study of dynamic three-dimensional contrast-enhanced ultrasound versus two-dimensional contrast-enhanced ultrasound in liver tumors [J]. Chinese Journal of Ultrasonography, 2012, 21(2): 133-137. 

[18] Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti- angiogenesis and normalization. Microvasc Res. 2007;74(2-3):72-84. 

[19] Xu Shiliang, Bao Bo. Study of three-dimensional power imaging in detecting cervical cancer and its correlation with MVD expression [J]. Chinese Journal of Ultrasound in Medicine, 2017, 33(9): 816-819.

[20] Makouei F, Ewertsen C, Agander TK, Olesen MV, Pakkenberg B, Todsen T. 3D Ultrasound versus Computed Tomography for Tumor Volume Measurement Compared to Gross Pathology-A Pilot Study on an Animal Model. J Imaging. 2022;8(12):329.

[21] Dong S, Peng YQ, Feng YN, et al. Based on 3D-PDU and clinical characteristics nomogram for prediction of lymph node metastasis and lymph-vascular space invasion of early cervical cancer preoperatively. BMC Womens Health. 2024;24(1):438. 

[22] Xu Y, Zhu L, Ru T, et al. Three-dimensional power Doppler ultrasound in the early assessment of response to concurrent chemo-radiotherapy for advanced cervical cancer. Acta Radiol. 2017; 58(9): 1147-1154. 

[23] Hsiao YH, Yang SF, Chen YH, et al. Updated applications of Ultrasound in Uterine Cervical Cancer. J Cancer. 2021;12(8):2181-2189. 

[24] Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol. 2007;188(6):1622-1635.

[25] Kanamoto H, Norimoto M, Eguchi Y, et al. Evaluating Spinal Canal Lesions Using Apparent Diffusion Coefficient Maps with Diffusion-Weighted Imaging. Asian Spine J. 2020;14(3):312-319.

[26] Messina C, Bignone R, Bruno A, et al. Diffusion-Weighted Imaging in Oncology: An Update. Cancers (Basel). 2020;12(6):1493. 

[27] Iima M, Le Bihan D. Clinical Intravoxel Incoherent Motion and Diffusion MR Imaging: Past, Present, and Future. Radiology. 2016;278(1):13-32.

[28] Szubert-Franczak AE, Naduk-Ostrowska M, Pasicz K, Podgórska J, Skrzyński W, Cieszanowski A. Intravoxel incoherent motion magnetic resonance imaging: basic principles and clinical applications. Pol J Radiol. 2020;85:e624-e635.

[29] Mesny E, Leporq B, Chapet O, Beuf O. Intravoxel incoherent motion magnetic resonance imaging to assess early tumor response to radiation therapy: Review and future directions. Magn Reson Imaging. 2024;108:129-137. 

[30] Wu Jiarui, Ji Qingyuan, Li Hongliang. Diagnostic value of HRMRI combined with IVIM-DWI in evaluating extramural vascular invasion of rectal cancer [J]. Chinese Journal of CT and MRI, 2024, 22(9): 143-145.

[31] Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging. 2002;16(4):407-422.

[32] Dappa E, Elger T, Hasenburg A, Düber C, Battista MJ, Hötker AM. The value of advanced MRI techniques in the assessment of cervical cancer: a review. Insights Imaging. 2017;8(5):471-481.